News

bit.bio will use Automata to automate a key aspect of its production of iPSC derived human cells

Our CEO gives his take on what's in store for the biotech industry in 2023 as part of this forward looking feature.

This series explores the fascinating interface between science and design. Episode 2 looks at synthetic biology and features our ...

Further products in CNS portfolio aim to address the translation gap and accelerate research and drug discovery for neurodegenerat...

bit.bio founder and CEO Dr Mark Kotter has 15 minutes to explain how we program biology as software to develop affordable next gen...

New advisors will provide important and independent guidance.

Products aim to address the translation gap and accelerate research and drug discovery for neurodegenerative disease.

bit.bio received a bronze award for its participation in the Green Impact awards for sustainability.